Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2025-06-02 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Please find the enclosed intimation in relation to the captioned subject for your reference.
Regulatory Filings
2025-06-02 English
Copy of Newspaper Publication
Regulatory Filings
2025-06-02 English
Please find the enclosed press release of the Company in relation to the financial results.
Earnings Release Classification · 95% confidence The document is a press release dated May 30, 2025, announcing the audited financial results for the financial year ended March 31, 2025. It includes detailed financial performance data such as total revenue, profit before and after tax, and segment-wise performance. The document also highlights key milestones, regulatory approvals, new product launches, key appointments, and recognitions. The presence of comprehensive financial data for the full fiscal year and management commentary indicates this is a full annual financial results announcement. The document is not merely an announcement of a report being published but contains substantive financial data and analysis. Therefore, it fits the definition of an Earnings Release (ER) as it is the initial announcement of the company's full year financial results with key highlights. The document length (9111 characters) supports it being more than a brief announcement but not a full annual report (10-K). Hence, the best classification is Earnings Release (ER).
2025-05-30 English
Updates
Earnings Release Classification · 95% confidence The document is a press release dated May 30, 2025, announcing the audited financial results for the financial year ended March 31, 2025. It includes detailed financial performance data such as total revenue, profit before and after tax, and segment-wise performance. The document also highlights key milestones, regulatory approvals, new product launches, and key appointments within the company. The presence of comprehensive financial data for the full fiscal year and management commentary indicates this is a full annual financial results announcement. The document is not merely an announcement of a report being published but contains substantive financial information and analysis. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights. It is not a full Annual Report (10-K) as it lacks the full detailed report content, nor is it a Management Discussion & Analysis (MDA) or Investor Presentation (IP). The document is too detailed and lengthy (9111 characters) to be a simple Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2025-05-30 English
Please find the enclosed Annual Secretarial Compliance Report of the Company for reference.
Regulatory Filings
2025-05-30 English
General Updates
Board/Management Information Classification · 95% confidence The document is a formal announcement addressed to stock exchanges regarding the appointment of a Secretarial Auditor by the Board of Directors, subject to approval at the upcoming Annual General Meeting. It references compliance with SEBI regulations and provides details about the appointment and the auditing firm. The document is short (3139 characters) and does not contain any financial statements or detailed financial data. It is an announcement of a board/management change related to auditor appointment rather than the audit report itself or any financial report. Therefore, it fits best under Board/Management Information (MANG).
2025-05-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.